AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-14. **(Canceled)**

15. **(Currently amended)** A method for treating arthritis comprising administering to a subject ~~an effective amount of~~ an anti-TNFα antibody, or an antigen-binding portion thereof, in a low dose of 0.01 – 0.1 mg/kg, such that the arthritis is treated.

16. **(Original)** The method of claim 15, wherein the arthritis is rheumatoid arthritis.

17. **(Previously presented)** The method of any one of claims 15 or 16, wherein arthritis is treated by alleviating symptoms selected from the group consisting of bone erosion, cartilage erosion, inflammation, and vascularity.

18-20. **(Canceled)**

21. **(Currently amended)** A low dose method for alleviating symptoms associated with arthritis comprising administering to a subject ~~an effective amount of~~ an anti-TNFα antibody, or an antigen-binding portion thereof, in a low dose of 0.01 – 0.1 mg/kg, such that the symptoms are alleviated.

22. **(Previously presented)** The method of claim 21, wherein the arthritis is rheumatoid arthritis.

23. **(Previously presented)** The method of any one of claims 21 or 22, wherein the symptoms are selected from the group consisting of bone erosion, cartilage erosion, inflammation, and vascularity.

24. **(Original)** The method of claim 23, wherein the symptoms are further selected from the group consisting of joint distortion, swelling, joint deformation, ankylosis on felxion, and severely impaired movement.

25-30. **(Canceled)**

31. **(Currently amended)** The method of any one of claims ~~1, 8, or~~ 15 or 21, wherein the anti-TNFα antibody, or an antigen-binding portion thereof, is administered with an additional therapeutic agent.

32-33. **(Canceled)**

34. **(Previously presented)** The method of any one of claims 15 or 16, wherein the anti-TNFα antibody, or an antigen-binding portion thereof, is either infliximab or D2E7.

35. **(Previously presented)** The method of any one of claims 21 or 22, wherein the anti-TNFα antibody, or an antigen-binding portion thereof, is either infliximab or D2E7.

36-39. **(Canceled)**

40. **(Previously presented)** The method of any one of claims 15, 16, 21 or 22, wherein the anti-TNFα antibody, or an antigen-binding portion thereof, is human.

41. **(Previously presented)** The method of claim 40, wherein the anti-TNFα antibody, or antigen-binding portion thereof, dissociates from human TNFα with a K_d of 1×10^{-8} M or less and a K_{off} rate constant of 1×10^{-3} s^{-1} or less, both determined by surface plasmon resonance, and neutralizes human TNFα cytotoxicity in a standard *in vitro* L929 assay with an IC_{50} of 1×10^{-7} M or less.

42. **(Currently amended)** A low dose method for treating rheumatoid arthritis comprising administering to a subject a low dose of 0.01 – 0.1 mg/kg of a human TNFα antibody, or an antigen-binding portion thereof, such that the rheumatoid arthritis is treated.

43. **(Previously presented)** The method of claim 42, wherein rheumatoid arthritis is treated by alleviating symptoms selected from the group consisting of bone erosion, cartilage erosion, inflammation, and vascularity, are treated.

44. **(Previously presented)** The method of claim 42, wherein the human anti-TNFα antibody, or antigen-binding portion thereof, dissociates from human TNFα with a K_d of 1×10^{-8} M or less and a K_{off} rate constant of 1×10^{-3} s^{-1} or less, both determined by surface

plasmon resonance, and neutralizes human TNFα cytotoxicity in a standard *in vitro* L929 assay with an IC_{50} of 1×10^{-7} M or less.

45. **(Previously presented)** The method of claim 44, wherein the anti-TNFα antibody, or antigen-binding portion thereof, is D2E7.

46-47. **(Canceled)**

48. **(Previously presented)** A low dose method of improving symptoms in the joints of a subject having arthritis comprising administering to the subject a low dose of 0.01-0.1 mg/kg of a human anti-TNFα antibody, or antigen-binding portion thereof, such that at least one symptom selected from the group consisting of inflammation, cartilage erosion, bone erosion, and vascularity is improved.

49. **(Previously presented)** The method of claim 48, wherein the human anti-TNFα antibody, or antigen-binding portion thereof, is D2E7.

50-51. **(Canceled)**

52. **(New)** A low dose method for treating arthritis comprising administering to a subject a human anti-TNFα antibody, or an antigen-binding portion thereof, in a low dose of 0.01 – 0.1 mg/kg, such that the arthritis is treated.

53. **(New)** A low dose method for alleviating symptoms associated with arthritis comprising administering to a subject an effective amount of a human anti-TNFα antibody, or an antigen-binding portion thereof, in a low dose of 0.01 – 0.1 mg/kg, such that the symptoms are alleviated.